Serotonin, inflammation, and IBS: Fitting the jigsaw together?

Journal of Pediatric Gastroenterology and Nutrition

Volumn 45, Issue SUPPL. 2, 2007, Pages

  Spiller, Robin ^a,b  

^a Wolfson Digestive Diseases Centre   (United Kingdom)

^b NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Infection; Inflammation; Irritable bowel syndrome; Serotonin

Indexed keywords

SEROTONIN; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SEROTONIN TRANSPORTER;

CAMPYLOBACTER; CLINICAL ASSESSMENT; CONFERENCE PAPER; CONSTIPATION; DEPRESSION; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIARRHEA; DISEASE SEVERITY; ENDOCRINE CELL; ENTERITIS; GASTROENTERITIS; GASTROINTESTINAL INFECTION; HISTOPATHOLOGY; HUMAN; HYPOCHONDRIASIS; LYMPHOCYTE COUNT; PREDICTOR VARIABLE; PRIORITY JOURNAL; RECTUM BIOPSY; RELIABILITY; RISK FACTOR; SALMONELLA; SEROTONIN RELEASE; SEX DIFFERENCE; SHIGELLA;

AGE FACTORS; BACTERIAL INFECTIONS; HUMANS; INFLAMMATION; IRRITABLE BOWEL SYNDROME; RISK FACTORS; SEROTONIN; SEX FACTORS;

ANIMALIA; CAMPYLOBACTER; SALMONELLA; SHIGELLA;

EID: 38149043436     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPG.0b013e31812e66da     Document Type: Conference Paper

References (40)

1. Thompson WG, Heaton KW, Smyth GT, et al. Irritable bowel syndrome in general practice: prevalence, characteristics, and referral. Gut 2000;46:78-82.
2. Wells NE, Hahn BA, Whorwell PJ. Clinical economics review: irritable bowel syndrome. Aliment Pharmacol Ther 1997;11:1019-30.
3. Longstreth GF, Hawkey CJ, Mayer EA, et al. Characteristics of patients with irritable bowel syndrome recruited from three sources: implications for clinical trials. Aliment Pharmacol Ther 2001;15:959-64.
4. Chaudhary NA, Truelove SC. The irritable colon syndrome. Q J Med 1962;123:307-22.
5. Dunlop SP, Jenkins D, Neal KR, et al. Clinical and histological features of post-infectious IBS: relative importance of enterochromaffin cell hyperplasia, anxiety, and depression. Gastroenterology 2003;125:1651-9.
6. Neal KR, Hebden J, Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. BMJ 1997;314:779-82.
7. McKendrick MW, Read NW. Irritable bowel syndrome - Post salmonella infection. J Infect 1994;29:1-3.
8. Gwee KA, Graham JC, McKendrick MW, et al. Psychometric scores and persistence of irritable bowel after infectious diarrhoea. Lancet 1996;347:150-3.
9. Thornley JP, Jenkins D, Neal K, et al. Relationship of Campylobacter toxigenicity in vitro to the development of postinfectious irritable bowel syndrome. J Infect Dis 2001;184:606-9.
10. Dunlop SP, Jenkins D, Neal KR, et al. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology 2003;125:1651-9.
11. Wang LH, Fang XC, Pan GZ. Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut 2004;53:1096-101.
12. Ji S, Park H, Lee D, et al. Post-infectious irritable bowel syndrome in patients with Shigella infection. J Gastroenterol Hepatol 2005;20:381-6.
13. Mearin F, Perez-Oliveras M, Perello A, et al. Dyspepsia and irritable bowel syndrome after a Salmonella gastroenteritis outbreak: one-year follow-up cohort study. Gastroenterology 2005;129:98-104.
14. Rodriguez LA, Ruigomez A. Increased risk of irritable bowel syndrome after bacterial gastroenteritis: cohort study. BMJ 1999;318:565-6.
15. Parry SD, Stansfield R, Jelley D, et al. Does bacterial gastroenteritis predispose people to functional gastrointestinal disorders? A prospective, community-based, case-control study. Am J Gastroenterol 2003;98:1970-5.
16. Gwee KA, Leong YL, Graham C, et al. The role of psychological and biological factors in postinfective gut dysfunction. Gut 1999;44:400-6.
17. Spiller RC, Jenkins D, Thornley JP, et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000;47:804-11.
18. Wheatcroft J, Wakelin D, Smith A, et al. Enterochromaffin cell hyperplasia and decreased serotonin transporter in a mouse model of postinfectious bowel dysfunction. Neurogastroenterol Motil 2005;17:863-70.
19. Kamal M, Wakelin D, Ouellette AJ, et al. Mucosal T cells regulate Paneth and intermediate cell numbers in the small intestine of T. spiralis-infected mice. Clin Exp Immunol 2001;126:117-1125.
20. De Ponti F. Pharmacology of serotonin: what a clinician should know. Gut 2004;53:1520-35.
21. Foley S, Harrison C, Johnson M, et al. Increased spontaneous 5HT release from jejunum of Trichinella infected mice. Neurogastroenterol Motil 2005;17 (Suppl 2):P47.
22. Weston AP, Biddle WL, Bhatia PS, et al. Terminal ileal mucosal mast cells in irritable bowel syndrome. Dig Dis Sci 1993;38:1590-5.
23. O'Sullivan M, Clayton N, Breslin NP, et al. Increased mast cells in the irritable bowel syndrome. Neurogastroenterol Motil 2000;12:449-57.
24. Chadwick VS, Chen W, Shu D, et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002;122:1778-83.
25. Dunlop SP, Jenkins D, Spiller RC. Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome. Am J Gastroenterol 2003;98:1578-83.
26. Barbara G, Stanghellini V, De Giorgio R, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004;126:693-702.
27. Dunlop SP, Hebden JM, Naesdal J, et al. Abnormal intestinal permeability in subgroups of diarrhoea predominant irritable bowel syndromes. Am J Gastroenterol 2006;101:1288-94.
28. Gwee KA, Collins SM, Read NW, et al. Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome. Gut 2003;52:523-6.
29. Scully P, O'Brien SO, Quigley EM, et al. Plasma levels of cytokines in patients with irritable bowel syndrome (IBS) compared to healthy controls. Gastroenterology 2005;128 (Suppl 2):A332.
30. O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005;128:541-51.
31. Dunlop SP, Coleman NS, Blackshaw E, et al. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005;3:349-57.
32. Atkinson W, Lockhart S, Whorwell PJ, et al. Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrheapredominant irritable bowel syndrome. Gastroenterology 2006;130:34-43.
33. Linden DR, Chen JX, Gershon MD, et al. Serotonin availability is increased in mucosa of guinea pigs with TNBS-induced colitis. Am J Physiol Gastrointest Liver Physiol 2003;285:G207-16.
34. Coleman N, Foley S, Dunlop SP, et al. Abnormalities of serotonin metabolism and its relation to symptoms in untreated celiac disease. Clin Gastroenterol Hepatol 2006;4:874-81.
35. El Salhy M, Danielsson A, Stenling R, et al. Colonic endocrine cells in inflammatory bowel disease. J Intern Med 1997;242:413-9.
36. Coates MD, Mahoney CR, Linden DR, et al. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 2004;126:1657-64.
37. Torres GE, Gainetdinov RR, Caron MG. Plasma membrane monoamine transporters: structure, regulation, and function. Nat Rev Neurosci 2003;4:13-25.
38. Bellini M, Rappelli L, Blandizzi C, et al. Platelet serotonin transporter in patients with diarrhea-predominant irritable bowel syndrome both before and after treatment with alosetron. Am J Gastroenterol 2003;98:2705-11.
39. Cremonini F, Delgado-Aros S, Camilleri M. Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Neurogastroenterol Motil 2003;15:79-86.
40. Evans BW, Clark WK, Moore DJ, et al. Tegaserod for the treatment of irritable bowel syndrome. Cochrane Database System Rev 2004;1:CD003960.